Skip to content

US · ERNA · BIOTECHNOLOGY

Ernexa Therapeutics Inc. (ERNA) intrinsic value and stock valuation

$1.36as of 2026-11-21 · Mkt cap 1.32M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Ernexa Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values ERNA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ERNA’s statements →

Ernexa Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02141 ernexatx.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$0.00
20152025
Net income
-$-14.08M
20152025
Free cash flow
-$-7.05M
20152025
Total equity
$2.4M-20.7% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$0.00$580K$70K$0.00$0.00
Operating income-$-9.32M-$-15.67M-$-21.14M-$-33.22M-$-113.73M
Net income-$-14.08M-$-44.54M-$-21.67M-$-24.58M-$-122.55M
EPSd-$-56.32M-$-39.07M-$-103.19M-$-204.83M-$-1.36B
Operating cash flow-$-7.02M-$-15.84M-$-20.41M-$-20.98M-$-23.49M
Capital expenditure-$-40K-$-370K-$-20K-$-300K-$-150K
Free cash flow-$-7.05M-$-16.2M-$-20.43M-$-21.27M-$-23.64M
Total assets$5.83M$5.27M$49.1M$22.3M$31.5M
Total debt$490K$680K$41.8M$4.14M$2.72M
Net debt-$-1.39M-$-1.04M$34.3M-$-7.31M-$-14.26M
Total equity$2.4M$1.7M$2.23M$12.1M$25.5M
Cash and short-term investments$1.88M$1.73M$7.58M$11.5M$17M
Income statement
20252024202320222021
Revenue$0.00$580K$70K$0.00$0.00
Cost of revenue$0.00$100K$240K$0.00$0.00
Gross profit$0.00$490K-$-170K$0.00$0.00
Research and development expenses$4.16M$4.6M$5.92M$10.4M$12.7M
Selling, general and administrative expenses$5.16M$13.1M$14.6M$16.6M$14.7M
Other expenses$0.00-$-1.58M$460K$6.27M$86.3M
Operating expenses$9.32M$16.2M$21M$33.2M$113.7M
Cost and expenses$9.32M$16.3M$21.2M$33.2M$113.7M
Interest income$80K$250K$140K$0.00$0.00
Interest expense$30K$6.75M$610K$30K$70K
Depreciation and amortization$260K$1.64M$1.12M$500K$460K
Ebitda-$-13.84M-$-36.12M-$-19.93M-$-24.01M-$-121.95M
Operating income-$-9.32M-$-15.67M-$-21.14M-$-33.22M-$-113.73M
Total other income/expenses, net-$-4.81M-$-28.84M-$-540K$8.68M-$-8.75M
Income before tax-$-14.13M-$-44.51M-$-21.67M-$-24.53M-$-122.48M
Income tax expense-$-40K$30K-$0.00$40K$60K
Net income-$-14.08M-$-44.54M-$-21.67M-$-24.58M-$-122.55M
Weighted average shares outstanding$250K$1.14M$210K$120K$90K
Weighted average diluted shares outstanding$250K$1.14M$210K$120K$90K
Balance sheet
20252024202320222021
Cash and short-term investments$1.88M$1.73M$7.58M$11.5M$17M
Net receivables$100K$440K$420K$950K$680K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$3.13M$2.35M$9.6M$13.7M$18.8M
Property, plant and equipment, net$550K$760K$33.3M$1.27M$3.24M
Goodwill and intangible assets$2.04M$2.04M$2.04M$2.04M$8.03M
Long-term investments$0.00$0.00$0.00$60K$1M
Total non-current assets$2.7M$2.92M$39.5M$8.6M$12.8M
Total assets$5.83M$5.27M$49.1M$22.3M$31.5M
Accounts payable$1.12M$1.72M$1.07M$1.62M$1.75M
Short-term debt$210K$210K$2.22M$2.04M$430K
Deferred revenue$0.00$0.00$190K$0.00$0.00
Total current liabilities$3.11M$2.94M$6.57M$7.65M$3.68M
Long-term debt$280K$480K$39.6M$2.09M$2.3M
Deferred revenue, non-current$0.00$0.00$390K$0.00$0.00
Total non-current liabilities$320K$630K$40.3M$2.52M$2.34M
Capital lease obligations$280K$480K$35.1M$1.18M$2.72M
Total liabilities$3.43M$3.57M$46.9M$10.2M$6.02M
Common stock$40K$260K$30K$30K$10K
Retained earnings-$-245.64M-$-231.54M-$-186.98M-$-165.3M-$-140.7M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$2.4M$1.7M$2.23M$12.1M$25.5M
Total investments$0.00$0.00$0.00$60K$1M
Total debt$490K$680K$41.8M$4.14M$2.72M
Net debt-$-1.39M-$-1.04M$34.3M-$-7.31M-$-14.26M
Cash flow statement
20252024202320222021
Net income-$-14.08M-$-44.54M-$-21.67M-$-24.58M-$-122.55M
Depreciation and amortization$260K$1.64M$1.12M$500K$460K
Stock-based compensation$1.5M$1.52M$1.24M$2.94M$5.24M
Change in working capital-$-50K-$-1.98M-$-2.12M$3.71M-$-2.29M
Accounts receivable-$-410K-$-10K$530K-$-260K-$-660K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$60K$180K-$-2.9M$2.03M-$-480K
Net cash provided by operating activities-$-7.02M-$-15.84M-$-20.41M-$-20.98M-$-23.49M
Investments in property, plant and equipment-$-40K-$-370K-$-20K-$-300K-$-150K
Acquisitions, net$0.00$0.00$0.00$0.00-$-22.71M
Net cash used for investing activities-$-40K-$-360K-$-20K-$-50K-$-22.74M
Common stock issued$4.96M$0.00$320K$19.7M$62.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00-$-20K-$-20K-$-10K
Net cash used for financing activities$7.21M$6.26M$16.6M$19.6M$61.6M
Net change in cash$150K-$-9.94M-$-3.87M-$-1.44M$15.4M
Cash at end of period$1.88M$1.73M$11.7M$15.5M$17M
Operating cash flow-$-7.02M-$-15.84M-$-20.41M-$-20.98M-$-23.49M
Capital expenditure-$-40K-$-370K-$-20K-$-300K-$-150K
Free cash flow-$-7.05M-$-16.2M-$-20.43M-$-21.27M-$-23.64M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Ernexa Therapeutics Inc.

        Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.

        CEO
        Sanjeev Luther
        Employees
        5
        Beta
        2.51

        Explore

        Frequently asked questions

        What is the intrinsic value of Ernexa Therapeutics Inc. (ERNA)?

        InvestorsCraft does not currently publish an intrinsic value for ERNA. How the IC value is calculated.

        Is ERNA undervalued?

        InvestorsCraft does not publish an undervaluation signal for ERNA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.